Advances in cardiovascular disease - Bristol Myers Squibb

A legacy of pioneering advances in cardiovascular disease

Looking back on a rich history and ahead toward a robust pipeline.

For more than 60 years, Bristol Myers Squibb has pioneered the science behind many of the game-changing advances in cardiovascular disease. As we have worked to bring forward new and transformative therapies for patients, our life-saving medicines have benefited millions of people around the world. We continue that work today. We are innovating next-generation medicines in areas of high unmet need such as arterial thrombosis, heart failure and cardiomyopathies. In late 2021, we announced promising research from AXIOMATIC-TKR, the first of two Phase 2 studies evaluating milvexian, our investigational oral factor XIa inhibitor (FXIa). AXIOMATIC-TKR is the first proof-of- principle study completed to demonstrate FXIa inhibition with a small-molecule drug has the potential to be an effective oral antithrombotic agent that does not increase risk of bleeding. Milvexian’s potential to be a safer oral anticoagulant could benefit a wider number of eligible patients who receive anticoagulation therapy–an important and promising advance.

Mavacamten is another important compound in our cardiovascular pipeline. Mavacamten is a potential first-in-class medicine targeting the underlying disease of symptomatic obstructive hypertrophic cardiomyopathy (HCM), a chronic heart disease that can potentially lead to debilitating symptoms and serious complications. HCM is a cardiovascular disease with serious unmet need, and we have ongoing clinical trials evaluating mavacamten’s potential ability to treat additional indications, including non-obstructive HCM.

HCM patient Regina McDermott Smyth has lost siblings, cousins and even children to heart disease. She entered a BMS clinical trial in 2018 and credits mavacamten with giving her hope for the future.

Patient Story

Hope across the generations

Read more >


More Science Stories


Transforming cells into cancer fighters >
The power of science, the power of AI >
Unleashing the immune system to fight cancer >
Transforming patients' lives through science

The touch that transforms

2021 Annual Report


Visit to see how we're bringing a human touch to everything we do. 

The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses. In addition, there is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at